Whilst standard therapeutic doses of semaglutide or liraglutide are carefully calibrated through extensive clinical trials, microdosing involves using a fraction of these established dosesoften below licensed starting doses
It is important to emphasize that there is currently no FDA-approved indication for GLP-1 receptor agonists in the treatment of alcohol use disorder (AUD)
Peminda Cabandugama, MD, an endocrinologist and obesity medicine specialist at Cleveland Clinic in Ohio, found the results to be slightly surprising. The pharmacokinetics [how drugs move through the body] of GLP-1 medications show a half-life of 5 days, which means the current standard of using these medications every 7 days is also stretching this out, says Dr
The SURPASS clinical trial program established tirzepatides efficacy profile across type 2 diabetes populations, demonstrating superior HbA1c reduction and weight loss versus comparator GLP-1 agonists including semaglutide
Avoid changing your dose or skipping injections on your own
This development is aimed at giving patients an oral option with the same power as an injection